2024
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer
Taylor J, Kamat A, Annapureddy D, Khene Z, Howard J, Tan W, McElree I, Facundo D, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y, O'Donnell M. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer. European Urology Oncology 2024, 8: 469-476. PMID: 39694798, DOI: 10.1016/j.euo.2024.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalAgedAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineDeoxycytidineDocetaxelFemaleGemcitabineHumansMaleMiddle AgedNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerBCG-unresponsive NMIBCBacillus Calmette-GuerinOncological outcomesBladder cancerIntravesical gemcitabineNon-muscle invasive bladder cancerBacillus Calmette-Guerin treatmentHazard ratioBacillus Calmette-Guerin therapyBacillus Calmette-Guerin groupCompare oncologic outcomesInvasive bladder cancerCox proportional hazard ratiosKaplan-Meier methodNoninvasive bladder cancerRates of PFSProportional hazard ratiosAssociated with lower ratesFood and Drug Administration guidelinesBCG-unresponsiveDrug Administration guidelinesGemcitabine-docetaxelBCG therapyProgression-Free
2023
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian Follow-UpInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removal
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply